1,720,997 research outputs found
The metabolic syndrome and insulin resistance are not risk factors for chronic kidney disease in obese non diabetic subjects.
No full textIl VEGF è correlato al rimodellamento ventricolare sinistro, ma non alla funzione renale in pazienti con diabete di tipo 2 ed ipertensione arteriosa.
No full textThe metabolic sindrome is not a risk factor for reduced kidney function in obese non diabetic subjects.
No full textPrevalenza di bassi livelli di colesterolo HDL e correlazione con il grado di controllo glicometabolico in pazienti con diabete di tipo 2.
No full textThe SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study
No full textBACKGROUND AND AIMS:
In a previous study, the single-nucleotide polymorphism (SNP) rs9677, mapped in the 3'-UTR of vasoactive intestinal peptide receptor 1 (VPAC1) gene, was found to be associated with type 2 diabetes (T2D) in Caucasian women. Moreover, the CC genotype correlated with a worse glycolipid profile. The objectives of this study were to confirm this correlation and assess the prevalence of coronary artery disease (CAD) in the previously investigated diabetic women after a follow-up of 4.6 years.
METHODS AND RESULTS:
A total of 143 women with T2D, with 53 carrying the CC genotype (age: 71.7 ± 7.4 years, diabetes duration: 17.2 ± 9.9 years) and 90 carrying the CT + TT genotypes (age: 69.4 ± 8.8 years, diabetes duration: 14.3 ± 8.2 years), were followed up for 4.6 ± 1.8 years. At follow-up, the clinical and haematochemical parameters were analysed. Twelve-lead electrocardiography, Doppler echocardiography and the percentage of patients with acute myocardial infarction (AMI) or of those subjected to coronary angioplasty and coronary artery bypass surgery were evaluated. At follow-up, there was no significant difference in terms of the clinical and haematochemical parameters between the two groups. However, despite a significantly increased use of statin therapy, no significant improvement in the LDL cholesterol levels was observed in CC female patients unlike those with CT + TT (P = 0.02). Moreover, the CC female patients presented a significantly higher percentage of echocardiographic abnormalities (P = 0.035), especially left ventricular (LV) diastolic dysfunction (P = 0.04).
CONCLUSIONS:
The rs9677 CC genotype could be correlated with a reduced response to statin therapy and seems to be involved in diabetes cardiomyopathy in female patients with T2D
The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension.
No full textAbstract. Background. Metabolic and hemodynamic factors concur to the development of diabetic nephropathy. Moreover, in diabetes, the presence of hypertension may accelerate the development of renal damage. Vascular Endothelial Growth Factor (VEGF) stimulates microvascular permeability, endothelium-dependent vasodilation and angiogenesis, and its synthesis is enhanced by hyperglycemia, Advanced Glycation End-products (AGEs), tissue hypoxia and hypertension. VEGF appears to play a central role in mediating diabetic vasculopathy, and although VEGF and its receptors are expressed at renal level, its action in renal pathophysiology is unknown. The aim of this study was to elucidate whether presence and/or severity of renal dysfunction is related to circulating VEGF in patients with type 2 diabetes and hypertension. Design and Methods. Fifty hypertensive type 2 diabetic patients and ten non-diabetic patients, were included in the study. Renal function parameters such as albumin excretion rate, (AER), and glomerular filtration rate (GFR), and VEGF plasma levels were analysed in all subjects, whereas %HbA1c and AGEs levels were evaluated in diabetic patients. Results. GFR was significantly decreased in diabetic patients compared with the control subjects (74.3615.95 vs. 118.0821.86 ml/min, p<0.0001). Three diabetic patients showed AER abnormalities (53.82.3 mg/24h). VEGF in diabetic patients was higher than in the control group (77.959.33 vs. 48.9214.77 pg/ml), but not significantly. %HbA1c and AGE levels were 6.60.2% and 11.598.09 UAGE, respectively. No correlation was found between renal function, circulating VEGF levels and metabolic control. Conclusions. Diabetes, in association with hypertension, significantly decreases renal function, but circulating VEGF may not reflect its concentration and action at renal level
Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives
Full text linkGestational diabetes mellitus (GDM) is a serious problem growing worldwide that needs to be addressed with urgency in consideration of the resulting severe complications for both mother and fetus. Growing evidence indicates that a healthy diet rich in fruit, vegetables, nuts, extra-virgin olive oil and fish has beneficial effects in both the prevention and management of several human diseases and metabolic disorders. In this review, we discuss the latest data concerning the effects of dietary bioactive compounds such as polyphenols and PUFA on the molecular mechanisms regulating glucose homoeostasis. Several studies, mostly based on in vitro and animal models, indicate that dietary polyphenols, mainly flavonoids, positively modulate the insulin signalling pathway by attenuating hyperglycaemia and insulin resistance, reducing inflammatory adipokines, and modifying microRNA (miRNA) profiles. Very few data about the influence of dietary exposure on GDM outcomes are available, although this approach deserves careful consideration. Further investigation, which includes exploring the 'omics' world, is needed to better understand the complex interaction between dietary compounds and GDM
Waist circumference reduction after insulin Detemir therapy in type 2 diabetes patients previously treated with NPH.
No full textBackground and aims: Abdominal weight may increase vascular complication risk. Insulin detemir reduces weight gain in comparison with NPH and insulin glargine. We studied the weight-sparing effect of detemir and assessed glycemic control and treatment satisfaction when switching from NPH to detemir, to improve metabolic control.
Methods and Results: Twenty type 2 diabetes (T2D) patients (mean age 59.4 years, BMI 7.5%, diabetes duration ≥12 months, previously treated with NPH) were recruited to this 20-week study. Patients received once-daily detemir (0.1 U/kg) at bedtime and OAD dose remained unchanged. HbA1c was measured at baseline and end-of-trial and DTSQ completed. Mean HbA1c (8.5±1.3 vs. 7.9±1.2%, P<0.05) and waist circumference (107.0±13.4 vs. 102.2±10.5 cm, P<0.05) were significantly reduced with detemir. Treatment satisfaction significantly improved (38.9±7.0 vs. 30.3±9.5, P<0.03). No weight gain was observed after treatment with insulin detemir (from 88.9±16.7 to 85.1±15.0 kg).
Conclusions: Detemir improves glycemic control for T2D patients previously on NPH, increases treatment satisfaction, and may provide additional weight-sparing benefits
- …
